# Clinical Study of Genakumab for Injection in Patients With Acute Gout

> **NCT05328531** · PHASE1,PHASE2 · COMPLETED · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 121 (actual)

## Conditions studied

- Acute Gout

## Interventions

- **DRUG:** Genakumab for Injection
- **DRUG:** Placebo for Genakumab for Injection

## Key facts

- **NCT ID:** NCT05328531
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-22
- **Primary completion:** 2022-06-09
- **Final completion:** 2022-06-09
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2025-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05328531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05328531, "Clinical Study of Genakumab for Injection in Patients With Acute Gout". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05328531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*